Platelet disorders in children: A diagnostic approach

Pediatric Blood and Cancer

Volumn 56, Issue 6, 2011, Pages 975-983

  Israels, Sara J ^a   Kahr, Walter H A ^b   Blanchette, Victor S ^b   Luban, Naomi L C ^c   Rivard, Georges E ^d   Rand, Margaret L ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Child; Platelet disorders; Platelet function tests; Review; Thrombocytopenia

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADRENALIN; AMINOCAPROIC ACID; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 QUEBEC; COLLAGEN; FIBRINOGEN; MYOSIN IIA; OSTEONECTIN; PADGEM PROTEIN; RISTOCETIN; THROMBIN; THROMBOPOIETIN RECEPTOR; THROMBOSPONDIN; THROMBOXANE A2; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UROKINASE; VON WILLEBRAND FACTOR;

ADRENAL DISEASE; ALGORITHM; AMEGAKARYOCYTIC THROMBOCYTOPENIA WITH RADIO ULNAR SYNOSTOSIS; ARTHROGRYPOSIS; AUTOSOMAL DOMINANT INHERITANCE; BERNARD SOULIER DISEASE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BONE MARROW EXAMINATION; CHILD; CHILDHOOD DISEASE; CHOLESTASIS; CLINICAL DEVELOPMENT PLAN; CLINICAL FEATURE; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; CONSANGUINITY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTRON MICROSCOPY; ENZYME BLOOD LEVEL; ETHNICITY; FIBRINOLYSIS; FLOW CYTOMETRY; GLANZMANN DISEASE; GRAY PLATELET SYNDROME; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOFLUORESCENCE TEST; INHERITANCE; LABORATORY TEST; LEUKOCYTE; LIGHT TRANSMISSION AGGREGOMETRY; MEGAKARYOPOIESIS; MICROTHROMBOCYTOPENIA; MONTREAL PLATELET SYNDROME; MUTATIONAL ANALYSIS; NEUTROPHIL; NONHUMAN; OPTICAL DENSITY; PEDIATRIC BLEEDING QUESTIONNAIRE; PHOTOMETER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUEBEC PLATELET DISORDER; QUESTIONNAIRE; REVIEW; SCREENING TEST; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE STRUCTURE; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME; X LINKED THROMBOCYTOPENIA;

ALGORITHMS; BLOOD COAGULATION FACTORS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CHILD; HUMANS; PLATELET FUNCTION TESTS; SYNDROME;

EID: 79952603038     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22988     Document Type: Review

References (79)

1. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-263.
2. Christie DJ, Avari T, Carrington LR, et al. Platelet function testing by aggregometry; approved guideline. 28. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. pp. 1-45. Available at
3. Knofler R, Olivieri M, Weickardt S, et al. First results of the THROMBKID study: A quality project for the registration of children and adolescents with hereditary platelet function defects in Germany, Austria and Switzerland. Hamostaseologie 2007; 27: 48-53.
4. Streif W, Knofler R, Eberl W. Inherited disorders of platelet function in pediatric clinical practice: A diagnostic challenge. Kin Padiatr 2010; 222: 203-208.
5. Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92: 357-365.
6. Philipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477-484.
7. Hayward CPM, Rao AK, Cattaneo M. Congenital platelet disorders: Overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006; 2 (Suppl 3): 128-136.
8. Balduini CL, Cattaneo M, Fabris F, et al. Inherited thrombocytopenias: A proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003; 88: 582-592.
9. Noris P, Pecci A, Di Bari F, et al. Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica 2004; 89: 1219-1225.
10. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-633.
11. Nurden P, Nurden A. Diagnostic assessment of platelet function. In: Kitchen S, Olson JD, Prestin FE, editors. Quality in laboratory hemostasis and thrombosis. Oxford: Blackwell Pub; 2009. pp. 110-124.
12. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010; 48: 579-598.
13. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-2626.
14. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-773.
15. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-2066.
16. McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104: 159-165.
17. Bowman M, Riddel J, Rand ML, et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7: 1418-1421.
18. Biss TT, Blanchette VS, Clark DS, et al. Quantitation of bleeding symptoms in children with von Willebrand disease: Use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8: 950-956.
19. Biss TT, Blanchette VS, Clark DS, et al. Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder. J Thromb Haemost 2010; 8: 1416-1419.
20. Israels SJ, El-Ekiaby M, Quiroga T, et al. Inherited disorders of platelet function and challenges to diagnosis of mucocutaneous bleeding. Haemophilia 2010; 16 (Suppl 5): 152-159.
21. Malok M, Titchener EH, Bridgers C, et al. Comparison of two platelet count estimation methodologies for peripheral blood smears. Clin Lab Sci 2007; 20: 154-160.
22. Nurden AT, Nurden P. The gray platelet syndrome: Clinical spectrum of the disease. Blood Rev 2007; 21: 21-36.
23. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189-203.
24. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24: 266-270.
25. Israels SJ. Diagnostic evaluation of platelet function disorders in neonates and children: An update. Semin Thromb Hemost 2009; 35: 181-188.
26. Bonduel M, Frontroth JP, Hepner M, et al. Platelet aggregation and adenosine triphosphate release values in children and adults. J Thromb Haemost 2007; 5: 1782-1787.
27. Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: Comparative study in 148 patients. J Thromb Haemost 2004; 2: 892-898.
28. Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? J Thromb Haemost 2004; 2: 890-891.
29. Roschitz B, Thaller S, Koestenberger M, et al. PFA-100 closure times in preoperative screening in 500 pediatric patients. Thromb Haemost 2007; 98: 243-247.
30. Harrison P. The role of PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.
31. Harrison P, Mumford A. Screening tests of platelet function: Update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009; 35: 150-157.
32. Robertson J, Lillicrap D, James PD. Von Willebrand disease. Pediatr Clin North Am 2008; 55: 377-392.
33. Daly ME, Dawood BB, Lester WA, et al. Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 2009; 113: 4110-4113.
34. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35: 158-167.
35. Moffat KA, Ledford-Kraemer MR, Nichols WL, et al. Variability in clinical laboratory practice in testing for disorders of platelet function: Results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93: 549-553.
36. Duncan EM, Bonar R, Rodgers SE, et al. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: Results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. Int J Lab Hematol 2009; 31: 398-406.
37. Jennings I, Woods TAL, Kitchen S, et al. Platelet function testing: Practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61: 950-954.
38. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
39. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Haemost 2009; 35: 168-1180.
40. Seyfert UT, Haubelt H, Vogt A, et al. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
41. Halimeh S, Angelis G, Sander A, et al. Multiplate® whole blood impedance point of care aggregometry: Preliminary reference values in healthy infants, children and adolescents. Klin Padiatr 2010; 222: 158-163.
42. Shapiro AD. Platelet function disorders. Haemophilia 2000; 6 (Suppl 1): 120-127.
43. Hayward CP. Diagnostic approach to platelet function disorders. Transfus Apher Sci 2008; 38: 65-76.
44. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: A question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008; 34: 113-127.
45. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-134.
46. Michelson AD, Linden MD, Barnard MR, et al. Flow cytometry. In: Michelson AD, editor. Platelets. San Diego: Academic Press; 2007. pp. 545-563.
47. Nurden A, Fiore M, Pillois X, et al. Genetic testing in the diagnostic evaluation of inherited platelet disorders. Semin Thromb Hemost 2009; 35: 204-212.
48. 2 and GPVI receptors. Hamostaseologie 2010; 30: 29-38.
49. White JG. Electron microscopy methods for studying platelet structure and function. Methods Mol Biol 2004; 272: 47-63.
50. Huizing M, Helip-Wooley A, Westbroek W, et al. Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008; 9: 359-386.
51. Ochs HD, Filipovich AH, Veys P, et al. Wiskott-Aldrich syndrome: Diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15 (Suppl 1): 84-90.
52. Balduini CL, Savoia A. Inherited thrombocytopenias: Molecular mechanisms. Semin Thromb Hemost 2004; 30: 513-523.
53. Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am 2009; 23: 321-331.
54. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-146.
55. Young G, Luban N, White JG. Giant platelet disorders in African-American children misdiagnosed as idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 1999; 21: 231-236.
56. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
57. Loffredo G, Baronciani L, Noris P, et al. von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets. Platelets 2006; 17: 149-152.
58. Savoia A, De Rocco D, Panza E, et al. Heavy chain myosin 9-related disease (MYH9 -RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103: 826-832.
59. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005; 130: 620-627.
60. Clausner S, Cramer-Borde E. Role of platelet electron microscopy in the diagnosis of platelet disorders. Semin Thromb Haemost 2009; 35: 213-223.
61. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, et al. Gray platelet syndrome: Natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010; 116: 4990-5001.
62. Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): A bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74: 1221-1228.
63. Hayward CP, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87: 4967-4978.
64. Janeway CM, Rivard GE, Tracy PB, et al. Factor V Quebec revisited. Blood 1996; 87: 3571-3578.
65. Lo B, Li L, Gissen P, et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet α-granule biogenesis. Blood 2005; 106: 4159-4166.
66. Hayward CP, Cramer EM, Kane WH, et al. Studies of a second family with the Quebec platelet disorder: Evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89: 1243-1253.
67. Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98: 257-265.
68. Sheth PM, Kahr WH, Haq MA, et al. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost 2003; 90: 293-298.
69. Diamandis M, Adam F, Kahr WH, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost 2006; 4: 1086-1094.
70. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: Ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 926-933.
71. Veljkovic DK, Rivard GE, Diamandis M, et al. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009; 113: 1535-1542.
72. Diamandis M, Paterson AD, Rommens JM, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 2009; 113: 1543-1546.
73. Paterson AD, Rommens JM, Bharaj B, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115: 1264-1266.
74. Lacombe M, D'Anglo G. Etudes sur une thrombopathie familiale. Nouv Rev Fr Hematol 1963; 3: 611-614.
75. Milton JG, Frojmovic MM. Shape-changing agents produce abnormally large platelets in a hereditary "giant platelets syndrome (MPS)". J Lab Clin Med 1979; 93: 154-161.
76. Milton JG, Frojmovic MM, Tang SS, et al. Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol 1984; 114: 336-345.
77. Okita JR, Frojmovic MM, Kristopeit S, et al. Montreal platelet syndrome: A defect in calcium-activated neutral proteinase (calpain). Blood 1989; 74: 715-721.
78. Jackson SC, Sinclair GD, Cloutier S, et al. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009; 113: 3348-3351.
79. Nurden P. The VWD2B saga continues to Montreal. Blood 2009; 113: 3134-3135.